Article

Comparison of the INNO-LiPA and PapType Assays for Detection of Human Papillomavirus in Archival Vulva Dysplasia and/or Neoplasia Tissue Biopsy Specimens

Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Victoria 3052, Australia.
Journal of clinical microbiology (Impact Factor: 4.23). 09/2011; 49(11):3980-2. DOI: 10.1128/JCM.00516-11
Source: PubMed

ABSTRACT INNO-LiPA and PapType human papillomavirus (HPV) genotyping assays were compared for detection of HPV genotypes on archival vulvar tissue. The INNO-LiPA assay detected 49 HPV-16 infections, compared with 47 detected by the PapType assay. The INNO-LiPA assay detected amplifiable DNA in 59 (91%) biopsy specimens, compared with 57 (88%) specimens for which amplifiable DNA was detected by the PapType assay. The two genotyping assays were highly comparable.

Download full-text

Full-text

Available from: Sepehr Tabrizi, Jul 30, 2015
1 Follower
 · 
120 Views
  • Source
    • "Cuzick). 1 Deceased. 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) in a single assay [7] [8], and assessed whether the identification of more HR HPV genotypes could improve the triage of HR HPV positive women. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background HR HPV genotypes when assayed collectively, achieve high sensitivity but low specificity for the prediction of CIN2+. Knowledge of the specific genotypes in an infection may facilitate the use of HR HPV detection in routine clinical practice. Objectives To compare the rate of HR HPV detection and the accuracy of CIN2+ prediction between PapType test (Genera Biosystems) and other commercially available HR HPV assays, and to examine the value of full HPV genotyping. Study design. PreservCyt samples from 1099 women referred for abnormal cervical cytology were used. CIN2+ was chosen as the primary end-point but CIN3+ was also evaluated. A hierarchy of HR HPV genotypes was created using PPV and this was used to create 3 groups of genotypes with potentially different management. Results The PapType assay has a specificity of 22.4% and a sensitivity of 94.6% for CIN2+ prediction. Classification into Groups A (HPV33 and HPV16, very highly predictive), B (HPV31, 18, 52, 35, 58, 51 highly predictive) and C (HPV68, 45, 39, 66, 56, 59, intermediate predictive) could double the specificity (44.5%) but only slightly reduce the sensitivity for CIN2+ (91.5%) and CIN3+ (94.0%). Conclusions The PapType assay is a simple, reproducible and effective test for HR HPV detection and genotyping. HPV 33 was found to have a very high PPV and should therefore be managed as for HPV16.
    Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology 05/2014; 60(1). DOI:10.1016/j.jcv.2014.02.002 · 3.47 Impact Factor
  • Source
    • "For paraffin-embedded archival samples, two commercially available assays utilizing PCR and targeting 65 and 150 bp region of L1 were used. The smaller amplicons are particularly suited for archival tissue [25] [26] [27]. 5–10 mm sections of FFPE archival tissue were deparaffinised with 800 í µí¼‡L histolene then mixed with 400 í µí¼‡L absolute ethanol. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective. We investigate the prevalence of human papillomavirus (HPV) in oesophageal squamous cell carcinoma (OSCC) tissues compared to oesophageal tissue from healthy controls, in an Australian cohort. Methods. We conducted a hospital-based case-control study of 99 patients with OSCC and 100 healthy controls to examine the presence of HPV DNA. Paraffin tissues were tested using the PapType high-risk HPV detection and genotyping kit and with INNO-LiPA HPV Genotyping Extra. The biopsy samples were tested for HPV using a PCR-ELISA method based on the L1 consensus primer set PGMY09-PGMY11. Results. HPV DNA of the oncogenic genotype 16 was detected in 1/99 case specimens, a rate of 1010 per 100,000 (95% CI: 30-5500). All control specimens were negative for HPV. Significantly higher rates of smoking, other aerodigestive cancers, and mortality were seen among cases than controls. A pooled analysis of this study and the only other Australian case-control study found that 9/321 cases and 0/155 controls were positive for HPV. The pooled odds ratio for HPV being a risk factor for OSCC was 9.35 (95% CI: 0.47-190.33). Conclusion. Our results suggest that in this multifactorial cancer HPV may be an additional risk factor; although a larger, better powered study is needed.
    Journal of Oncology 04/2014; 2014:236482. DOI:10.1155/2014/236482
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: PapType human papillomavirus (HPV) assay was compared to Hybrid Capture 2 (HC2), Amplicor (Amp), and Linear Array (LA) HPV tests in 894 women undergoing management for a high-grade Pap smear abnormality. The sensitivity in detection of underlying high-grade histological diagnosis by PapType was 90.3% and by HC2 was 79.8%, while by Amp and LA it was 92.4% and 91.6%, respectively. The specificities were 52.5%, 55.3%, 49.4%, and 51.7% for PapType, HC2, Amp, and LA, respectively. Copyright © 2012, American Society for Microbiology. All Rights Reserved.
    Journal of clinical microbiology 05/2012; 50(8):2796-8. DOI:10.1128/JCM.01064-12 · 4.23 Impact Factor
Show more